1141 - 1150 of 7939 Results
Title
Year
-
OPENTitle: A Severe Case of Lupus CerebritisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903100.95793.8aBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S9.full.pdfCitation Count: 1
- An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 Therapies2022OPENTitle: An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 TherapiesJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903428.98962.0aBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S52.full.pdfCitation Count: 0
- Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD2022OPENTitle: Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PDJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 333End Page: 338Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29284Best OA location URL: https://doi.org/10.1002/mds.29284Citation Count: 15
- Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls2022OPENTitle: Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy ControlsJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903096.36040.1dBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S8.full.pdfCitation Count: 0
- Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects2022OPENTitle: Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effectsJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 13Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1038/s41467-022-34732-5Best OA location URL: https://www.nature.com/articles/s41467-022-34732-5.pdfCitation Count: 30
- Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences2022OPENTitle: Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 SequencesJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903160.72715.2dBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S17.1.full.pdfCitation Count: 1
- Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)2022OPENTitle: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S40.full.pdfCitation Count: 1
-
OPENTitle: Substitution of PINK1 Gly411 modulates substrate receptivity and turnoverJournal Name: AutophagyPublisher: Informa UK LimitedVol: 19Issue #: 6Start Page: 1711End Page: 1732Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/15548627.2022.2151294Best OA location URL: https://doi.org/10.1080/15548627.2022.2151294Citation Count: 11
- The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis2022OPENTitle: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S39.full.pdfCitation Count: 2
- Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-Encephalitis2022RESTRICTEDTitle: Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903424.19914.85Citation Count: 0